TV News LIES

Friday, Nov 28th

Last update09:22:34 PM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Ebola vaccine from Glaxo passes early safety test

Ebola vaccineAn experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects and produced an immune...

Coca-Cola's new venture: Expensive milk

coca cola milkWith soda sales sagging, Coca-Cola is moving into the dairy business. It plans to offer milk...

Smoking levels reach all-time low in the United States

Smoking at all time low in USAmericans are kicking the habit in record numbers. According to the Centers for Disease Control and...

Vancouver Experiments With Prescription Heroin

Prescription heroinVancouver, one of North America's most progressive cities in respect to drug policy, will conduct a...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!